BACKGROUND: HIV-1 infection has been associated with high expression of CD38 on peripheral blood (PB) CD8+ and CD4+ T-cells, which has been related with poor prognosis in untreated HIV-1+ patients. In turn, CD38 expression on PB monocytes from HIV-1+ individuals and its behavior after starting antiretroviral therapy (ART) have been poorly studied. METHODS: CD38 expression on PB CD8+ and CD4+ T-lymphocytes and monocytes was prospectively analyzed in 30 ART-naive HIV-1+ patients, using a quantitative multiparameter flow cytometry approach. Patients were tested prior to therapy, and at weeks +2, +4, +8, +12, and +52 after ART. RESULTS: Prior to ART, CD38 expression was significantly increased on PB CD8+ and CD4+ T-cells and monocytes; despite a significant decrease after ART, CD38 expression remained abnormally high on PB CD8+ T-cells and monocytes, even after one year of therapy, in the absence of detectable plasma viral load. The ART-induced early changes on CD38 expression by PB T-cells and monocytes differed among the cell subsets analyzed and patient groups, probably reflecting an interaction between the direct effects of therapy and a redistribution of the PB compartments of T-cells and monocytes. Hierarchical clustering analysis showed that the overall pattern of changes in CD38 expression observed early after starting ART was predictive of a better response to therapy, not only for PB CD8+ T-cells, but also for CD4+ T-cells and monocytes. Accordingly, those HIV-1+ patients, who experienced a more pronounced increase in CD38 expression on both PB CD4+ T-cells and monocytes after 2 weeks of ART, showed a more rapid viral clearance, which might reflect decreased HIV-1 replication in lymph nodes and other tissues, and a partial restoration of hematopoiesis. CONCLUSIONS: Combined quantitative measurement of CD38 expression on PB monocytes, and CD8+ and CD4+ T-cells is a more useful tool for monitoring HIV-1+ patients under ART, rather than quantitation of CD38 expression on PB CD8+ T-lymphocytes alone. (c) 2006 International Society for Analytical Cytology.
BACKGROUND:HIV-1 infection has been associated with high expression of CD38 on peripheral blood (PB) CD8+ and CD4+ T-cells, which has been related with poor prognosis in untreated HIV-1+ patients. In turn, CD38 expression on PB monocytes from HIV-1+ individuals and its behavior after starting antiretroviral therapy (ART) have been poorly studied. METHODS:CD38 expression on PB CD8+ and CD4+ T-lymphocytes and monocytes was prospectively analyzed in 30 ART-naive HIV-1+ patients, using a quantitative multiparameter flow cytometry approach. Patients were tested prior to therapy, and at weeks +2, +4, +8, +12, and +52 after ART. RESULTS: Prior to ART, CD38 expression was significantly increased on PB CD8+ and CD4+ T-cells and monocytes; despite a significant decrease after ART, CD38 expression remained abnormally high on PB CD8+ T-cells and monocytes, even after one year of therapy, in the absence of detectable plasma viral load. The ART-induced early changes on CD38 expression by PB T-cells and monocytes differed among the cell subsets analyzed and patient groups, probably reflecting an interaction between the direct effects of therapy and a redistribution of the PB compartments of T-cells and monocytes. Hierarchical clustering analysis showed that the overall pattern of changes in CD38 expression observed early after starting ART was predictive of a better response to therapy, not only for PB CD8+ T-cells, but also for CD4+ T-cells and monocytes. Accordingly, those HIV-1+ patients, who experienced a more pronounced increase in CD38 expression on both PB CD4+ T-cells and monocytes after 2 weeks of ART, showed a more rapid viral clearance, which might reflect decreased HIV-1 replication in lymph nodes and other tissues, and a partial restoration of hematopoiesis. CONCLUSIONS: Combined quantitative measurement of CD38 expression on PB monocytes, and CD8+ and CD4+ T-cells is a more useful tool for monitoring HIV-1+ patients under ART, rather than quantitation of CD38 expression on PB CD8+ T-lymphocytes alone. (c) 2006 International Society for Analytical Cytology.
Authors: Sheila M Keating; Elizabeth T Golub; Marek Nowicki; Mary Young; Kathryn Anastos; Howard Crystal; Mardge H Cohen; Jinbing Zhang; Ruth M Greenblatt; Seema Desai; Shiquan Wu; Alan L Landay; Stephen J Gange; Philip J Norris Journal: AIDS Date: 2011-09-24 Impact factor: 4.177
Authors: Rachel E Owen; John W Heitman; Dale F Hirschkorn; Marion C Lanteri; Hope H Biswas; Jeffrey N Martin; Melissa R Krone; Steven G Deeks; Philip J Norris Journal: AIDS Date: 2010-05-15 Impact factor: 4.177
Authors: R E Abrams; K Pierre; N El-Murr; E Seung; L Wu; E Luna; R Mehta; J Li; K Larabi; M Ahmed; V Pelekanou; Z-Y Yang; H van de Velde; S K Stamatelos Journal: Sci Rep Date: 2022-06-29 Impact factor: 4.996
Authors: Abraham J Olivier; Lindi Masson; Katharina Ronacher; Gerhard Walzl; David Coetzee; David A Lewis; Anna-Lise Williamson; Jo-Ann S Passmore; Wendy A Burgers Journal: J Infect Dis Date: 2013-11-23 Impact factor: 5.226
Authors: Marco Schunter; Hiutung Chu; Timothy L Hayes; Delandy McConnell; Sean S Crawford; Paul A Luciw; Stig Bengmark; David M Asmuth; Jennifer Brown; Charles L Bevins; Barbara L Shacklett; J William Critchfield Journal: BMC Complement Altern Med Date: 2012-06-29 Impact factor: 3.659